nodes	percent_of_prediction	percent_of_DWPC	metapath
Cilazapril—Lisinopril—systemic scleroderma	0.329	1	CrCtD
Cilazapril—ACE—systemic scleroderma	0.17	1	CbGaD
Cilazapril—ACE—Lisinopril—systemic scleroderma	0.0733	0.364	CbGbCtD
Cilazapril—Enalapril—Captopril—systemic scleroderma	0.0567	0.242	CrCrCtD
Cilazapril—ACE—Captopril—systemic scleroderma	0.0548	0.272	CbGbCtD
Cilazapril—Fosinopril—Lisinopril—systemic scleroderma	0.0307	0.131	CrCrCtD
Cilazapril—SLC15A1—Lisinopril—systemic scleroderma	0.0294	0.146	CbGbCtD
Cilazapril—Moexipril—Lisinopril—systemic scleroderma	0.0231	0.0986	CrCrCtD
Cilazapril—SLC15A1—Captopril—systemic scleroderma	0.022	0.109	CbGbCtD
Cilazapril—Spirapril—Lisinopril—systemic scleroderma	0.02	0.0852	CrCrCtD
Cilazapril—Ramipril—Lisinopril—systemic scleroderma	0.0187	0.0799	CrCrCtD
Cilazapril—Enalapril—Lisinopril—systemic scleroderma	0.0187	0.0799	CrCrCtD
Cilazapril—Trandolapril—Lisinopril—systemic scleroderma	0.0187	0.0799	CrCrCtD
Cilazapril—Nateglinide—Lisinopril—systemic scleroderma	0.0167	0.0713	CrCrCtD
Cilazapril—Quinapril—Lisinopril—systemic scleroderma	0.0159	0.0677	CrCrCtD
Cilazapril—Benazepril—Lisinopril—systemic scleroderma	0.0151	0.0645	CrCrCtD
Cilazapril—ABCB1—Lisinopril—systemic scleroderma	0.00721	0.0358	CbGbCtD
Cilazapril—ABCB1—Captopril—systemic scleroderma	0.0054	0.0268	CbGbCtD
Cilazapril—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00425	0.0211	CbGbCtD
Cilazapril—ACE—forelimb zeugopod—systemic scleroderma	0.00345	0.233	CbGeAlD
Cilazapril—ABCB1—Prednisone—systemic scleroderma	0.0034	0.0169	CbGbCtD
Cilazapril—ACE—pulmonary artery—systemic scleroderma	0.00258	0.174	CbGeAlD
Cilazapril—ACE—skeletal joint—systemic scleroderma	0.00228	0.154	CbGeAlD
Cilazapril—ABCB1—Methotrexate—systemic scleroderma	0.00171	0.00846	CbGbCtD
Cilazapril—ACE—umbilical vein—systemic scleroderma	0.0017	0.115	CbGeAlD
Cilazapril—ACE—artery—systemic scleroderma	0.000956	0.0647	CbGeAlD
Cilazapril—ACE—endothelium—systemic scleroderma	0.000807	0.0546	CbGeAlD
Cilazapril—ACE—blood vessel—systemic scleroderma	0.000745	0.0504	CbGeAlD
Cilazapril—SLC15A1—digestive system—systemic scleroderma	0.000385	0.026	CbGeAlD
Cilazapril—ACE—connective tissue—systemic scleroderma	0.000382	0.0258	CbGeAlD
Cilazapril—ACE—smooth muscle tissue—systemic scleroderma	0.000349	0.0236	CbGeAlD
Cilazapril—ACE—digestive system—systemic scleroderma	0.000276	0.0187	CbGeAlD
Cilazapril—ABCB1—blood vessel—systemic scleroderma	0.000262	0.0177	CbGeAlD
Cilazapril—Fosinopril—ACE—systemic scleroderma	0.00024	0.136	CrCbGaD
Cilazapril—ACE—lung—systemic scleroderma	0.00023	0.0156	CbGeAlD
Cilazapril—SLC15A2—lung—systemic scleroderma	0.000201	0.0136	CbGeAlD
Cilazapril—Perindopril—ACE—systemic scleroderma	0.000196	0.111	CrCbGaD
Cilazapril—Spirapril—ACE—systemic scleroderma	0.000194	0.109	CrCbGaD
Cilazapril—Moexipril—ACE—systemic scleroderma	0.000186	0.105	CrCbGaD
Cilazapril—Quinapril—ACE—systemic scleroderma	0.000173	0.0974	CrCbGaD
Cilazapril—Lisinopril—ACE—systemic scleroderma	0.000173	0.0974	CrCbGaD
Cilazapril—Ramipril—ACE—systemic scleroderma	0.000167	0.0943	CrCbGaD
Cilazapril—Trandolapril—ACE—systemic scleroderma	0.000167	0.0943	CrCbGaD
Cilazapril—Benazepril—ACE—systemic scleroderma	0.00015	0.0847	CrCbGaD
Cilazapril—Enalapril—ACE—systemic scleroderma	0.000127	0.0715	CrCbGaD
Cilazapril—ABCB1—digestive system—systemic scleroderma	9.71e-05	0.00657	CbGeAlD
Cilazapril—ABCB1—lung—systemic scleroderma	8.11e-05	0.00548	CbGeAlD
Cilazapril—Dyspnoea—Mycophenolic acid—systemic scleroderma	4.2e-05	0.000871	CcSEcCtD
Cilazapril—Somnolence—Mycophenolic acid—systemic scleroderma	4.19e-05	0.000869	CcSEcCtD
Cilazapril—Shock—Lisinopril—systemic scleroderma	4.18e-05	0.000866	CcSEcCtD
Cilazapril—Angioedema—Mycophenolate mofetil—systemic scleroderma	4.16e-05	0.000864	CcSEcCtD
Cilazapril—Thrombocytopenia—Lisinopril—systemic scleroderma	4.16e-05	0.000862	CcSEcCtD
Cilazapril—Dyspepsia—Mycophenolic acid—systemic scleroderma	4.15e-05	0.00086	CcSEcCtD
Cilazapril—Neutropenia—Prednisone—systemic scleroderma	4.15e-05	0.00086	CcSEcCtD
Cilazapril—Tachycardia—Lisinopril—systemic scleroderma	4.14e-05	0.000859	CcSEcCtD
Cilazapril—Abdominal pain—Azathioprine—systemic scleroderma	4.14e-05	0.000858	CcSEcCtD
Cilazapril—Skin disorder—Lisinopril—systemic scleroderma	4.12e-05	0.000855	CcSEcCtD
Cilazapril—Malaise—Mycophenolate mofetil—systemic scleroderma	4.11e-05	0.000852	CcSEcCtD
Cilazapril—Hyperhidrosis—Lisinopril—systemic scleroderma	4.1e-05	0.000851	CcSEcCtD
Cilazapril—Diarrhoea—Captopril—systemic scleroderma	4.1e-05	0.000851	CcSEcCtD
Cilazapril—Decreased appetite—Mycophenolic acid—systemic scleroderma	4.1e-05	0.00085	CcSEcCtD
Cilazapril—Vertigo—Mycophenolate mofetil—systemic scleroderma	4.09e-05	0.000849	CcSEcCtD
Cilazapril—Syncope—Mycophenolate mofetil—systemic scleroderma	4.09e-05	0.000848	CcSEcCtD
Cilazapril—Erectile dysfunction—Prednisone—systemic scleroderma	4.08e-05	0.000847	CcSEcCtD
Cilazapril—Leukopenia—Mycophenolate mofetil—systemic scleroderma	4.08e-05	0.000846	CcSEcCtD
Cilazapril—Feeling abnormal—Leflunomide—systemic scleroderma	4.07e-05	0.000844	CcSEcCtD
Cilazapril—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	4.07e-05	0.000844	CcSEcCtD
Cilazapril—Fatigue—Mycophenolic acid—systemic scleroderma	4.06e-05	0.000843	CcSEcCtD
Cilazapril—Nausea—Mometasone—systemic scleroderma	4.05e-05	0.000841	CcSEcCtD
Cilazapril—Anorexia—Lisinopril—systemic scleroderma	4.05e-05	0.000839	CcSEcCtD
Cilazapril—Gastrointestinal pain—Leflunomide—systemic scleroderma	4.04e-05	0.000838	CcSEcCtD
Cilazapril—Ataxia—Methotrexate—systemic scleroderma	4.03e-05	0.000836	CcSEcCtD
Cilazapril—Constipation—Mycophenolic acid—systemic scleroderma	4.03e-05	0.000836	CcSEcCtD
Cilazapril—Pain—Mycophenolic acid—systemic scleroderma	4.03e-05	0.000836	CcSEcCtD
Cilazapril—Palpitations—Mycophenolate mofetil—systemic scleroderma	4.03e-05	0.000835	CcSEcCtD
Cilazapril—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	4.01e-05	0.000831	CcSEcCtD
Cilazapril—Hyperglycaemia—Prednisone—systemic scleroderma	4e-05	0.000829	CcSEcCtD
Cilazapril—Cough—Mycophenolate mofetil—systemic scleroderma	3.98e-05	0.000825	CcSEcCtD
Cilazapril—Hypotension—Lisinopril—systemic scleroderma	3.97e-05	0.000823	CcSEcCtD
Cilazapril—Dizziness—Captopril—systemic scleroderma	3.96e-05	0.000822	CcSEcCtD
Cilazapril—Liver function test abnormal—Methotrexate—systemic scleroderma	3.96e-05	0.000821	CcSEcCtD
Cilazapril—Hypertension—Mycophenolate mofetil—systemic scleroderma	3.93e-05	0.000816	CcSEcCtD
Cilazapril—Urticaria—Leflunomide—systemic scleroderma	3.92e-05	0.000814	CcSEcCtD
Cilazapril—Abdominal pain—Leflunomide—systemic scleroderma	3.91e-05	0.00081	CcSEcCtD
Cilazapril—Acute coronary syndrome—Prednisone—systemic scleroderma	3.9e-05	0.000808	CcSEcCtD
Cilazapril—Feeling abnormal—Mycophenolic acid—systemic scleroderma	3.88e-05	0.000805	CcSEcCtD
Cilazapril—Arthralgia—Mycophenolate mofetil—systemic scleroderma	3.88e-05	0.000805	CcSEcCtD
Cilazapril—Chest pain—Mycophenolate mofetil—systemic scleroderma	3.88e-05	0.000805	CcSEcCtD
Cilazapril—Myalgia—Mycophenolate mofetil—systemic scleroderma	3.88e-05	0.000805	CcSEcCtD
Cilazapril—Myocardial infarction—Prednisone—systemic scleroderma	3.87e-05	0.000804	CcSEcCtD
Cilazapril—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	3.87e-05	0.000802	CcSEcCtD
Cilazapril—Anxiety—Mycophenolate mofetil—systemic scleroderma	3.87e-05	0.000802	CcSEcCtD
Cilazapril—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	3.86e-05	0.000801	CcSEcCtD
Cilazapril—Hypersensitivity—Azathioprine—systemic scleroderma	3.85e-05	0.000799	CcSEcCtD
Cilazapril—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	3.85e-05	0.000799	CcSEcCtD
Cilazapril—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	3.85e-05	0.000799	CcSEcCtD
Cilazapril—Insomnia—Lisinopril—systemic scleroderma	3.84e-05	0.000796	CcSEcCtD
Cilazapril—Discomfort—Mycophenolate mofetil—systemic scleroderma	3.83e-05	0.000795	CcSEcCtD
Cilazapril—Paraesthesia—Lisinopril—systemic scleroderma	3.81e-05	0.000791	CcSEcCtD
Cilazapril—Vomiting—Captopril—systemic scleroderma	3.81e-05	0.00079	CcSEcCtD
Cilazapril—Dry mouth—Mycophenolate mofetil—systemic scleroderma	3.79e-05	0.000787	CcSEcCtD
Cilazapril—Dyspnoea—Lisinopril—systemic scleroderma	3.78e-05	0.000785	CcSEcCtD
Cilazapril—Rash—Captopril—systemic scleroderma	3.78e-05	0.000784	CcSEcCtD
Cilazapril—Dermatitis—Captopril—systemic scleroderma	3.78e-05	0.000783	CcSEcCtD
Cilazapril—Somnolence—Lisinopril—systemic scleroderma	3.77e-05	0.000783	CcSEcCtD
Cilazapril—Headache—Captopril—systemic scleroderma	3.76e-05	0.000779	CcSEcCtD
Cilazapril—Confusional state—Mycophenolate mofetil—systemic scleroderma	3.75e-05	0.000778	CcSEcCtD
Cilazapril—Dyspepsia—Lisinopril—systemic scleroderma	3.74e-05	0.000775	CcSEcCtD
Cilazapril—Abdominal pain—Mycophenolic acid—systemic scleroderma	3.73e-05	0.000773	CcSEcCtD
Cilazapril—Oedema—Mycophenolate mofetil—systemic scleroderma	3.72e-05	0.000771	CcSEcCtD
Cilazapril—Decreased appetite—Lisinopril—systemic scleroderma	3.69e-05	0.000765	CcSEcCtD
Cilazapril—Gastrointestinal disorder—Lisinopril—systemic scleroderma	3.66e-05	0.00076	CcSEcCtD
Cilazapril—Fatigue—Lisinopril—systemic scleroderma	3.66e-05	0.000759	CcSEcCtD
Cilazapril—Shock—Mycophenolate mofetil—systemic scleroderma	3.66e-05	0.000759	CcSEcCtD
Cilazapril—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	3.64e-05	0.000755	CcSEcCtD
Cilazapril—Hypersensitivity—Leflunomide—systemic scleroderma	3.64e-05	0.000755	CcSEcCtD
Cilazapril—Pancreatitis—Methotrexate—systemic scleroderma	3.63e-05	0.000753	CcSEcCtD
Cilazapril—Pain—Lisinopril—systemic scleroderma	3.63e-05	0.000753	CcSEcCtD
Cilazapril—Constipation—Lisinopril—systemic scleroderma	3.63e-05	0.000753	CcSEcCtD
Cilazapril—Tachycardia—Mycophenolate mofetil—systemic scleroderma	3.63e-05	0.000753	CcSEcCtD
Cilazapril—Skin disorder—Mycophenolate mofetil—systemic scleroderma	3.61e-05	0.000749	CcSEcCtD
Cilazapril—Bradycardia—Prednisone—systemic scleroderma	3.61e-05	0.000749	CcSEcCtD
Cilazapril—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	3.6e-05	0.000746	CcSEcCtD
Cilazapril—Diarrhoea—Azathioprine—systemic scleroderma	3.58e-05	0.000742	CcSEcCtD
Cilazapril—Nausea—Captopril—systemic scleroderma	3.56e-05	0.000738	CcSEcCtD
Cilazapril—Anorexia—Mycophenolate mofetil—systemic scleroderma	3.55e-05	0.000735	CcSEcCtD
Cilazapril—Asthenia—Leflunomide—systemic scleroderma	3.54e-05	0.000735	CcSEcCtD
Cilazapril—Feeling abnormal—Lisinopril—systemic scleroderma	3.5e-05	0.000725	CcSEcCtD
Cilazapril—Pruritus—Leflunomide—systemic scleroderma	3.5e-05	0.000725	CcSEcCtD
Cilazapril—Hypotension—Mycophenolate mofetil—systemic scleroderma	3.48e-05	0.000721	CcSEcCtD
Cilazapril—Gastrointestinal pain—Lisinopril—systemic scleroderma	3.47e-05	0.00072	CcSEcCtD
Cilazapril—Dysuria—Methotrexate—systemic scleroderma	3.46e-05	0.000719	CcSEcCtD
Cilazapril—Neutropenia—Methotrexate—systemic scleroderma	3.46e-05	0.000719	CcSEcCtD
Cilazapril—Dizziness—Azathioprine—systemic scleroderma	3.46e-05	0.000717	CcSEcCtD
Cilazapril—Erectile dysfunction—Methotrexate—systemic scleroderma	3.41e-05	0.000708	CcSEcCtD
Cilazapril—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	3.39e-05	0.000703	CcSEcCtD
Cilazapril—Photosensitivity reaction—Methotrexate—systemic scleroderma	3.38e-05	0.000701	CcSEcCtD
Cilazapril—Asthenia—Mycophenolic acid—systemic scleroderma	3.38e-05	0.000701	CcSEcCtD
Cilazapril—Diarrhoea—Leflunomide—systemic scleroderma	3.38e-05	0.000701	CcSEcCtD
Cilazapril—Urticaria—Lisinopril—systemic scleroderma	3.37e-05	0.000699	CcSEcCtD
Cilazapril—Insomnia—Mycophenolate mofetil—systemic scleroderma	3.36e-05	0.000698	CcSEcCtD
Cilazapril—Abdominal pain—Lisinopril—systemic scleroderma	3.36e-05	0.000696	CcSEcCtD
Cilazapril—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	3.34e-05	0.000693	CcSEcCtD
Cilazapril—Pruritus—Mycophenolic acid—systemic scleroderma	3.33e-05	0.000692	CcSEcCtD
Cilazapril—Vomiting—Azathioprine—systemic scleroderma	3.33e-05	0.00069	CcSEcCtD
Cilazapril—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	3.32e-05	0.000688	CcSEcCtD
Cilazapril—Somnolence—Mycophenolate mofetil—systemic scleroderma	3.31e-05	0.000686	CcSEcCtD
Cilazapril—Rash—Azathioprine—systemic scleroderma	3.3e-05	0.000684	CcSEcCtD
Cilazapril—Dermatitis—Azathioprine—systemic scleroderma	3.3e-05	0.000683	CcSEcCtD
Cilazapril—Flushing—Prednisone—systemic scleroderma	3.29e-05	0.000683	CcSEcCtD
Cilazapril—Headache—Azathioprine—systemic scleroderma	3.28e-05	0.00068	CcSEcCtD
Cilazapril—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	3.28e-05	0.000679	CcSEcCtD
Cilazapril—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	3.27e-05	0.000679	CcSEcCtD
Cilazapril—Dizziness—Leflunomide—systemic scleroderma	3.27e-05	0.000678	CcSEcCtD
Cilazapril—Renal failure—Methotrexate—systemic scleroderma	3.25e-05	0.000674	CcSEcCtD
Cilazapril—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	3.23e-05	0.000671	CcSEcCtD
Cilazapril—Diarrhoea—Mycophenolic acid—systemic scleroderma	3.22e-05	0.000669	CcSEcCtD
Cilazapril—Angiopathy—Prednisone—systemic scleroderma	3.22e-05	0.000668	CcSEcCtD
Cilazapril—Conjunctivitis—Methotrexate—systemic scleroderma	3.21e-05	0.000666	CcSEcCtD
Cilazapril—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	3.21e-05	0.000666	CcSEcCtD
Cilazapril—Immune system disorder—Prednisone—systemic scleroderma	3.21e-05	0.000665	CcSEcCtD
Cilazapril—Pain—Mycophenolate mofetil—systemic scleroderma	3.18e-05	0.00066	CcSEcCtD
Cilazapril—Constipation—Mycophenolate mofetil—systemic scleroderma	3.18e-05	0.00066	CcSEcCtD
Cilazapril—Arrhythmia—Prednisone—systemic scleroderma	3.17e-05	0.000657	CcSEcCtD
Cilazapril—Vomiting—Leflunomide—systemic scleroderma	3.14e-05	0.000651	CcSEcCtD
Cilazapril—Alopecia—Prednisone—systemic scleroderma	3.14e-05	0.00065	CcSEcCtD
Cilazapril—Hypersensitivity—Lisinopril—systemic scleroderma	3.13e-05	0.000649	CcSEcCtD
Cilazapril—Hepatobiliary disease—Methotrexate—systemic scleroderma	3.12e-05	0.000648	CcSEcCtD
Cilazapril—Dizziness—Mycophenolic acid—systemic scleroderma	3.12e-05	0.000646	CcSEcCtD
Cilazapril—Epistaxis—Methotrexate—systemic scleroderma	3.12e-05	0.000646	CcSEcCtD
Cilazapril—Rash—Leflunomide—systemic scleroderma	3.11e-05	0.000646	CcSEcCtD
Cilazapril—Dermatitis—Leflunomide—systemic scleroderma	3.11e-05	0.000645	CcSEcCtD
Cilazapril—Nausea—Azathioprine—systemic scleroderma	3.11e-05	0.000644	CcSEcCtD
Cilazapril—Headache—Leflunomide—systemic scleroderma	3.09e-05	0.000642	CcSEcCtD
Cilazapril—Agranulocytosis—Methotrexate—systemic scleroderma	3.08e-05	0.000639	CcSEcCtD
Cilazapril—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	3.07e-05	0.000636	CcSEcCtD
Cilazapril—Asthenia—Lisinopril—systemic scleroderma	3.05e-05	0.000632	CcSEcCtD
Cilazapril—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	3.04e-05	0.000631	CcSEcCtD
Cilazapril—Pruritus—Lisinopril—systemic scleroderma	3e-05	0.000623	CcSEcCtD
Cilazapril—Vomiting—Mycophenolic acid—systemic scleroderma	3e-05	0.000621	CcSEcCtD
Cilazapril—Rash—Mycophenolic acid—systemic scleroderma	2.97e-05	0.000616	CcSEcCtD
Cilazapril—Dermatitis—Mycophenolic acid—systemic scleroderma	2.97e-05	0.000616	CcSEcCtD
Cilazapril—Urticaria—Mycophenolate mofetil—systemic scleroderma	2.95e-05	0.000613	CcSEcCtD
Cilazapril—Headache—Mycophenolic acid—systemic scleroderma	2.95e-05	0.000612	CcSEcCtD
Cilazapril—Pharyngitis—Methotrexate—systemic scleroderma	2.94e-05	0.00061	CcSEcCtD
Cilazapril—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	2.94e-05	0.00061	CcSEcCtD
Cilazapril—Nausea—Leflunomide—systemic scleroderma	2.93e-05	0.000609	CcSEcCtD
Cilazapril—Urinary tract disorder—Methotrexate—systemic scleroderma	2.93e-05	0.000607	CcSEcCtD
Cilazapril—Urethral disorder—Methotrexate—systemic scleroderma	2.91e-05	0.000603	CcSEcCtD
Cilazapril—Diarrhoea—Lisinopril—systemic scleroderma	2.9e-05	0.000602	CcSEcCtD
Cilazapril—Ill-defined disorder—Prednisone—systemic scleroderma	2.87e-05	0.000594	CcSEcCtD
Cilazapril—Visual impairment—Methotrexate—systemic scleroderma	2.86e-05	0.000593	CcSEcCtD
Cilazapril—Anaemia—Prednisone—systemic scleroderma	2.86e-05	0.000592	CcSEcCtD
Cilazapril—Angioedema—Prednisone—systemic scleroderma	2.82e-05	0.000585	CcSEcCtD
Cilazapril—Dizziness—Lisinopril—systemic scleroderma	2.81e-05	0.000582	CcSEcCtD
Cilazapril—Erythema multiforme—Methotrexate—systemic scleroderma	2.8e-05	0.000582	CcSEcCtD
Cilazapril—Nausea—Mycophenolic acid—systemic scleroderma	2.8e-05	0.000581	CcSEcCtD
Cilazapril—Malaise—Prednisone—systemic scleroderma	2.79e-05	0.000578	CcSEcCtD
Cilazapril—Vertigo—Prednisone—systemic scleroderma	2.78e-05	0.000576	CcSEcCtD
Cilazapril—Syncope—Prednisone—systemic scleroderma	2.77e-05	0.000575	CcSEcCtD
Cilazapril—Tinnitus—Methotrexate—systemic scleroderma	2.77e-05	0.000573	CcSEcCtD
Cilazapril—Cardiac disorder—Methotrexate—systemic scleroderma	2.75e-05	0.000571	CcSEcCtD
Cilazapril—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	2.74e-05	0.000568	CcSEcCtD
Cilazapril—Loss of consciousness—Prednisone—systemic scleroderma	2.72e-05	0.000563	CcSEcCtD
Cilazapril—Vomiting—Lisinopril—systemic scleroderma	2.7e-05	0.00056	CcSEcCtD
Cilazapril—Angiopathy—Methotrexate—systemic scleroderma	2.69e-05	0.000558	CcSEcCtD
Cilazapril—Immune system disorder—Methotrexate—systemic scleroderma	2.68e-05	0.000556	CcSEcCtD
Cilazapril—Rash—Lisinopril—systemic scleroderma	2.68e-05	0.000555	CcSEcCtD
Cilazapril—Dermatitis—Lisinopril—systemic scleroderma	2.67e-05	0.000555	CcSEcCtD
Cilazapril—Asthenia—Mycophenolate mofetil—systemic scleroderma	2.67e-05	0.000553	CcSEcCtD
Cilazapril—Hypertension—Prednisone—systemic scleroderma	2.67e-05	0.000553	CcSEcCtD
Cilazapril—Chills—Methotrexate—systemic scleroderma	2.66e-05	0.000552	CcSEcCtD
Cilazapril—Headache—Lisinopril—systemic scleroderma	2.66e-05	0.000552	CcSEcCtD
Cilazapril—Pruritus—Mycophenolate mofetil—systemic scleroderma	2.63e-05	0.000546	CcSEcCtD
Cilazapril—Myalgia—Prednisone—systemic scleroderma	2.63e-05	0.000545	CcSEcCtD
Cilazapril—Arthralgia—Prednisone—systemic scleroderma	2.63e-05	0.000545	CcSEcCtD
Cilazapril—Anxiety—Prednisone—systemic scleroderma	2.62e-05	0.000544	CcSEcCtD
Cilazapril—Alopecia—Methotrexate—systemic scleroderma	2.62e-05	0.000544	CcSEcCtD
Cilazapril—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	2.61e-05	0.000542	CcSEcCtD
Cilazapril—Discomfort—Prednisone—systemic scleroderma	2.6e-05	0.000539	CcSEcCtD
Cilazapril—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	2.54e-05	0.000528	CcSEcCtD
Cilazapril—Dysgeusia—Methotrexate—systemic scleroderma	2.53e-05	0.000524	CcSEcCtD
Cilazapril—Nausea—Lisinopril—systemic scleroderma	2.52e-05	0.000523	CcSEcCtD
Cilazapril—Oedema—Prednisone—systemic scleroderma	2.52e-05	0.000523	CcSEcCtD
Cilazapril—Shock—Prednisone—systemic scleroderma	2.48e-05	0.000514	CcSEcCtD
Cilazapril—Tachycardia—Prednisone—systemic scleroderma	2.46e-05	0.00051	CcSEcCtD
Cilazapril—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.46e-05	0.00051	CcSEcCtD
Cilazapril—Skin disorder—Prednisone—systemic scleroderma	2.45e-05	0.000508	CcSEcCtD
Cilazapril—Hyperhidrosis—Prednisone—systemic scleroderma	2.44e-05	0.000505	CcSEcCtD
Cilazapril—Anorexia—Prednisone—systemic scleroderma	2.4e-05	0.000498	CcSEcCtD
Cilazapril—Ill-defined disorder—Methotrexate—systemic scleroderma	2.4e-05	0.000497	CcSEcCtD
Cilazapril—Anaemia—Methotrexate—systemic scleroderma	2.39e-05	0.000495	CcSEcCtD
Cilazapril—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.36e-05	0.00049	CcSEcCtD
Cilazapril—Rash—Mycophenolate mofetil—systemic scleroderma	2.35e-05	0.000486	CcSEcCtD
Cilazapril—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.34e-05	0.000486	CcSEcCtD
Cilazapril—Headache—Mycophenolate mofetil—systemic scleroderma	2.33e-05	0.000483	CcSEcCtD
Cilazapril—Malaise—Methotrexate—systemic scleroderma	2.33e-05	0.000483	CcSEcCtD
Cilazapril—Vertigo—Methotrexate—systemic scleroderma	2.32e-05	0.000481	CcSEcCtD
Cilazapril—Leukopenia—Methotrexate—systemic scleroderma	2.31e-05	0.000479	CcSEcCtD
Cilazapril—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.3e-05	0.000476	CcSEcCtD
Cilazapril—Insomnia—Prednisone—systemic scleroderma	2.28e-05	0.000473	CcSEcCtD
Cilazapril—Paraesthesia—Prednisone—systemic scleroderma	2.26e-05	0.00047	CcSEcCtD
Cilazapril—Cough—Methotrexate—systemic scleroderma	2.25e-05	0.000467	CcSEcCtD
Cilazapril—Dyspepsia—Prednisone—systemic scleroderma	2.22e-05	0.00046	CcSEcCtD
Cilazapril—Nausea—Mycophenolate mofetil—systemic scleroderma	2.21e-05	0.000458	CcSEcCtD
Cilazapril—Chest pain—Methotrexate—systemic scleroderma	2.2e-05	0.000456	CcSEcCtD
Cilazapril—Myalgia—Methotrexate—systemic scleroderma	2.2e-05	0.000456	CcSEcCtD
Cilazapril—Arthralgia—Methotrexate—systemic scleroderma	2.2e-05	0.000456	CcSEcCtD
Cilazapril—Decreased appetite—Prednisone—systemic scleroderma	2.19e-05	0.000455	CcSEcCtD
Cilazapril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.18e-05	0.000453	CcSEcCtD
Cilazapril—Fatigue—Prednisone—systemic scleroderma	2.17e-05	0.000451	CcSEcCtD
Cilazapril—Discomfort—Methotrexate—systemic scleroderma	2.17e-05	0.00045	CcSEcCtD
Cilazapril—Constipation—Prednisone—systemic scleroderma	2.16e-05	0.000447	CcSEcCtD
Cilazapril—Confusional state—Methotrexate—systemic scleroderma	2.12e-05	0.000441	CcSEcCtD
Cilazapril—Feeling abnormal—Prednisone—systemic scleroderma	2.08e-05	0.000431	CcSEcCtD
Cilazapril—Thrombocytopenia—Methotrexate—systemic scleroderma	2.06e-05	0.000428	CcSEcCtD
Cilazapril—Gastrointestinal pain—Prednisone—systemic scleroderma	2.06e-05	0.000428	CcSEcCtD
Cilazapril—Skin disorder—Methotrexate—systemic scleroderma	2.05e-05	0.000424	CcSEcCtD
Cilazapril—Hyperhidrosis—Methotrexate—systemic scleroderma	2.04e-05	0.000422	CcSEcCtD
Cilazapril—Anorexia—Methotrexate—systemic scleroderma	2.01e-05	0.000417	CcSEcCtD
Cilazapril—Urticaria—Prednisone—systemic scleroderma	2e-05	0.000415	CcSEcCtD
Cilazapril—Abdominal pain—Prednisone—systemic scleroderma	1.99e-05	0.000413	CcSEcCtD
Cilazapril—Hypotension—Methotrexate—systemic scleroderma	1.97e-05	0.000408	CcSEcCtD
Cilazapril—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	1.92e-05	0.000398	CcSEcCtD
Cilazapril—Insomnia—Methotrexate—systemic scleroderma	1.91e-05	0.000395	CcSEcCtD
Cilazapril—Paraesthesia—Methotrexate—systemic scleroderma	1.89e-05	0.000392	CcSEcCtD
Cilazapril—Dyspnoea—Methotrexate—systemic scleroderma	1.88e-05	0.00039	CcSEcCtD
Cilazapril—Somnolence—Methotrexate—systemic scleroderma	1.87e-05	0.000388	CcSEcCtD
Cilazapril—Hypersensitivity—Prednisone—systemic scleroderma	1.86e-05	0.000385	CcSEcCtD
Cilazapril—Dyspepsia—Methotrexate—systemic scleroderma	1.85e-05	0.000385	CcSEcCtD
Cilazapril—Decreased appetite—Methotrexate—systemic scleroderma	1.83e-05	0.00038	CcSEcCtD
Cilazapril—Gastrointestinal disorder—Methotrexate—systemic scleroderma	1.82e-05	0.000377	CcSEcCtD
Cilazapril—Fatigue—Methotrexate—systemic scleroderma	1.82e-05	0.000377	CcSEcCtD
Cilazapril—Asthenia—Prednisone—systemic scleroderma	1.81e-05	0.000375	CcSEcCtD
Cilazapril—Pain—Methotrexate—systemic scleroderma	1.8e-05	0.000374	CcSEcCtD
Cilazapril—Pruritus—Prednisone—systemic scleroderma	1.78e-05	0.00037	CcSEcCtD
Cilazapril—Feeling abnormal—Methotrexate—systemic scleroderma	1.74e-05	0.00036	CcSEcCtD
Cilazapril—Diarrhoea—Prednisone—systemic scleroderma	1.73e-05	0.000358	CcSEcCtD
Cilazapril—Gastrointestinal pain—Methotrexate—systemic scleroderma	1.72e-05	0.000357	CcSEcCtD
Cilazapril—Urticaria—Methotrexate—systemic scleroderma	1.67e-05	0.000347	CcSEcCtD
Cilazapril—Dizziness—Prednisone—systemic scleroderma	1.67e-05	0.000346	CcSEcCtD
Cilazapril—Abdominal pain—Methotrexate—systemic scleroderma	1.67e-05	0.000345	CcSEcCtD
Cilazapril—Vomiting—Prednisone—systemic scleroderma	1.6e-05	0.000332	CcSEcCtD
Cilazapril—Rash—Prednisone—systemic scleroderma	1.59e-05	0.00033	CcSEcCtD
Cilazapril—Dermatitis—Prednisone—systemic scleroderma	1.59e-05	0.000329	CcSEcCtD
Cilazapril—Headache—Prednisone—systemic scleroderma	1.58e-05	0.000328	CcSEcCtD
Cilazapril—Hypersensitivity—Methotrexate—systemic scleroderma	1.55e-05	0.000322	CcSEcCtD
Cilazapril—Asthenia—Methotrexate—systemic scleroderma	1.51e-05	0.000314	CcSEcCtD
Cilazapril—Nausea—Prednisone—systemic scleroderma	1.5e-05	0.000311	CcSEcCtD
Cilazapril—Pruritus—Methotrexate—systemic scleroderma	1.49e-05	0.000309	CcSEcCtD
Cilazapril—Diarrhoea—Methotrexate—systemic scleroderma	1.44e-05	0.000299	CcSEcCtD
Cilazapril—Dizziness—Methotrexate—systemic scleroderma	1.39e-05	0.000289	CcSEcCtD
Cilazapril—Vomiting—Methotrexate—systemic scleroderma	1.34e-05	0.000278	CcSEcCtD
Cilazapril—Rash—Methotrexate—systemic scleroderma	1.33e-05	0.000276	CcSEcCtD
Cilazapril—Dermatitis—Methotrexate—systemic scleroderma	1.33e-05	0.000275	CcSEcCtD
Cilazapril—Headache—Methotrexate—systemic scleroderma	1.32e-05	0.000274	CcSEcCtD
Cilazapril—Nausea—Methotrexate—systemic scleroderma	1.25e-05	0.00026	CcSEcCtD
